Since the signaling pathways such as the type-I interferon (IFN) signaling involved in the lupus pathogenesis requires JAK/STAT, tofacitinib may also be effective in the treatment of SLE. This evidence concerns the gene SOAT1 and systemic lupus erythematosus.